Jennifer E Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4115214/publications.pdf

Version: 2024-02-01

48	965	18	29
papers	citations	h-index	g-index
51	51	51	1129
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	IgE-Mediated Food Allergy. Clinical Reviews in Allergy and Immunology, 2019, 57, 244-260.	2.9	190
2	Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open, 2015, 5, e009758.	0.8	71
3	The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clinical Trials, 2015, 12, 503-510.	0.7	59
4	Adherence to the International Committee of Medical Journal Editors' (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals. Trials, 2018, 19, 448.	0.7	49
5	Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open, 2017, 7, e017917.	0.8	46
6	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials, 2017, 18, 333.	0.7	43
7	Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ: British Medical Journal, 2019, 366, I4217.	2.4	40
8	Ethical issues in pediatric emergency mass critical care. Pediatric Critical Care Medicine, 2011, 12, S163-S168.	0.2	37
9	Gatekeepers for pragmatic clinical trials. Clinical Trials, 2015, 12, 442-448.	0.7	32
10	Quality of life in food allergic children. Annals of Allergy, Asthma and Immunology, 2020, 124, 379-384.	0.5	32
11	Just allocation of COVID-19 vaccines. BMJ Global Health, 2021, 6, e004812.	2.0	28
12	Delays in the Publication of Important Clinical Trial Findings in Oncology. JAMA Oncology, 2018, 4, e180264.	3.4	26
13	Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials, 2018, 19, 581.	0.7	24
14	Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. JAMA Network Open, 2021, 4, e217075.	2.8	24
15	Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials. JAMA Network Open, 2021, 4, e2134233.	2.8	24
16	Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs. JAMA Network Open, 2018, 1, e180283.	2.8	23
17	Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open, 2021, 4, e217063.	2.8	22
18	Characterizing expanded access and compassionate use programs for experimental drugs. BMC Research Notes, 2017, 10, 350.	0.6	20

#	Article	IF	CITATIONS
19	Racial Privilege and Medical Student Awards: Addressing Racial Disparities in Alpha Omega Alpha Honor Society Membership. Journal of General Internal Medicine, 2020, 35, 3348-3351.	1.3	20
20	Diversity in clinical research: public health and social justice imperatives. Journal of Medical Ethics, 2023, 49, 200-203.	1.0	15
21	Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. BMC Medicine, 2019, 17, 117.	2.3	14
22	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. Circulation, 2021, 143, e1035-e1087.	1.6	13
23	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. Journal of the American College of Cardiology, 2021, 77, 3079-3133.	1.2	12
24	From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, and Rating. Journal of Law, Medicine and Ethics, 2013, 41, 601-610.	0.4	11
25	COVID-19 vaccine research and the trouble with clinical equipoise. Lancet, The, 2021, 397, 576.	6.3	10
26	Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees. Journal of Medical Ethics, 2016, 42, 229-234.	1.0	9
27	Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. BMJ Open, 2021, 11, e053248.	0.8	8
28	Direct-to-consumer personal genomic tests need better regulation. Nature Medicine, 2021, 27, 940-943.	15.2	7
29	Bioethical accreditation or rating needed to restore trust in pharma. Nature Medicine, 2013, 19, 261-261.	15.2	6
30	Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. Lancet, The, 2020, 395, 926-928.	6.3	6
31	Impact of the National Institutes of Health Consensus Development Program on stimulating National Institutes of Health–funded research, 1998 to 2001. International Journal of Technology Assessment in Health Care, 2007, 23, 343-348.	0.2	5
32	Managing acute agitation and aggression in the world of drug shortages. Mental Health Clinician, 2021, 11, 334-346.	0.5	5
33	Aspects of Hausa intonation, 1: utterances in isolation. Journal of the International Phonetic Association, 1980, 10, 45-63.	0.6	4
34	Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. Human Psychopharmacology, 2015, 30, 350-355.	0.7	4
35	Ethical considerations in international clinical trial site selection. BMJ Global Health, 2022, 7, e008012.	2.0	4
36	Aspects of Hausa intonation, 2: continuous text. Journal of the International Phonetic Association, 1982, 12, 78-93.	0.6	3

#	Article	IF	CITATIONS
37	Irreligious Bioethics, Nonsense on Stilts?. American Journal of Bioethics, 2012, 12, 15-17.	0.5	3
38	How a Clinical Trial Registry Became a Symbol of Misinformation. Hastings Center Report, 2013, 43, 11-12.	0.7	3
39	Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover. American Journal of Bioethics, 2021, 21, 86-88.	0.5	3
40	Implementation of 21st Century Cures Act Expanded Access Policies Requirements. Clinical Pharmacology and Therapeutics, 2021, 110, 1579-1584.	2.3	3
41	Tenâ€year experience of unrelated bone marrow donor transplants in children with malignant and nonâ€malignant conditions. Pediatric Transplantation, 1999, 3, 49-59.	0.5	2
42	BioCEP. Cambridge Quarterly of Healthcare Ethics, 2012, 21, 409-416.	0.5	2
43	Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 249-255.	0.7	2
44	Blood, Sweat, and Fears: A Novel Mutation Associated With Anaphylaxis and Nonresponse in a Patient With Afibrinogenemia. Journal of Pediatric Hematology/Oncology, 2021, 43, e260-e263.	0.3	1
45	Editorial Comments—Pandemic Influenza Triage in the Clinical Setting. Prehospital and Disaster Medicine, 2010, 25, 105-106.	0.7	O
46	Developing Drugs DifferentlyGood Pharma: The Public-Health Model Of The Mario Negri Institute By Light Donald W. Maturo Antonio F. London (UK) : Palgrave Macmillan , 2015 300Âpp., \$95.00. Health Affairs, 2015, 34, 2202-2202.	2.5	0
47	Skin testing with different food formulations in pediatric patients with eosinophilic esophagitis. Pediatric Allergy and Immunology, 2020, 31, 329-332.	1.1	0
48	Therapeutic Orphans. The National Catholic Bioethics Quarterly, 2019, 19, 27-35.	0.1	0